Q1 2024 Earnings Forecast for LENZ Therapeutics, Inc. (NASDAQ:LENZ) Issued By Leerink Partnrs

LENZ Therapeutics, Inc. (NASDAQ:LENZ) – Research analysts at Leerink Partnrs issued their Q1 2024 earnings estimates for LENZ Therapeutics in a research report issued to clients and investors on Monday, April 15th. Leerink Partnrs analyst M. Goodman anticipates that the company will earn ($0.51) per share for the quarter. Leerink Partnrs currently has a “Outperform” rating on the stock. Leerink Partnrs also issued estimates for LENZ Therapeutics’ Q2 2024 earnings at ($0.47) EPS, Q3 2024 earnings at ($0.40) EPS, Q4 2024 earnings at ($0.42) EPS, FY2024 earnings at ($1.80) EPS, FY2025 earnings at ($2.20) EPS, FY2026 earnings at ($1.30) EPS, FY2027 earnings at $0.85 EPS and FY2028 earnings at $2.70 EPS.

A number of other research firms have also commented on LENZ. SVB Leerink initiated coverage on shares of LENZ Therapeutics in a research note on Monday. They set an “outperform” rating and a $32.00 price objective for the company. Citigroup initiated coverage on shares of LENZ Therapeutics in a research note on Wednesday, April 10th. They set a “buy” rating and a $34.00 price objective for the company. Piper Sandler initiated coverage on shares of LENZ Therapeutics in a research note on Wednesday, March 27th. They set an “overweight” rating and a $28.00 price objective for the company. Finally, William Blair initiated coverage on shares of LENZ Therapeutics in a research note on Monday. They set an “outperform” rating for the company. Five research analysts have rated the stock with a buy rating, According to data from MarketBeat, the company currently has an average rating of “Buy” and an average price target of $31.33.

LENZ Therapeutics Stock Down 11.1 %

LENZ stock opened at $17.70 on Wednesday. LENZ Therapeutics has a one year low of $14.07 and a one year high of $29.82. The stock has a market cap of $147.26 million, a price-to-earnings ratio of -1.13 and a beta of 0.20.

Insider Activity

In other news, Director Ra Capital Management, L.P. acquired 998,009 shares of the company’s stock in a transaction that occurred on Thursday, March 21st. The shares were purchased at an average price of $15.03 per share, for a total transaction of $15,000,075.27. Following the completion of the acquisition, the director now owns 3,319,339 shares of the company’s stock, valued at approximately $49,889,665.17. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. 38.40% of the stock is owned by corporate insiders.

About LENZ Therapeutics

LENZ Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing aceclidine-based eye drop to enhance vision in patients diagnosed with presbyopia. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California.